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Abstract Facioscapulohumeral dystrophy (FSHD) is a rare
inherited neuromuscular disease estimated to affect
1/15,000 people. Through basic research, remarkable pro-
gress has been made towards the development of targeted
therapies. Patient identification, through registries or other
means is essential for trial-readiness. The UK FSHD
Patient Registry is a patient initiated registry that collects
standardised and internationally agreed dataset of self-re-
ported clinical details combined with professionally veri-
fied genetic information. It includes four additional
questionnaires to capture patient reported outcomes related
to pain, quality of life and scapular fixation. Between 2013
and 2015, 518 patients registered 243 males, 241 females
with a mean age of 47.8 years. Most of the patients have
FSHD type 1 (91.7 %), and weakness of the facial
(59.2 %) was the most prevalent symptom at onset, fol-
lowed by shoulder-girdle muscles (53.3 %) and distal
(22.45 %) or proximal lower limb weakness (14.8 %).
85.57 % patients were ambulant or ambulant with assis-
tance at the time of registration, 7.9 % report respiratory
insufficiency. The registry has demonstrated utility with the
recruitment of patients for a natural history study of
infantile onset FSHD, and the longitudinal analysis of
patient-related outcomes will provide much-needed base-
line information to power future trials. The internationally
agreed core dataset enables national registries to participate
in a ‘‘Global FSHD registry’’. We suggest that the reg-
istry’s ability to interoperate with other large datasets will
be instrumental for sharing and exploiting data globally.
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Introduction
FSHD one of the three most frequent neuromuscular dis-
orders [1] with an estimated prevalence of 1/15,000–1/
20,000 [2, 3]. There is currently no treatment to slow down,
reverse or cure the symptoms of FSHD. Symptoms usually
start around the second decade and are characterised by
progressive and sometimes markedly asymmetric muscle
weakness, affecting the facial, scapular or humeral mus-
cles. Later on, muscle weakness may involve the abdomi-
nal muscles and the muscles of the legs and feet [4]. FSHD
is an autosomal dominant disease associated in the majority
of patients (95 %) with a contraction of a polymorphic
repeat D4Z4 on chromosome 4qA (FSHD1) [5–7]. In 5 %
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of FSHD patients there is a normal or intermediate length
of the D4Z4 macrosatellite. Recently, mutations in the
SMCHD1 gene (structural maintenance of chromosomes
flexible hinge domain containing 1) have been described in
patients with an FSHD phenotype and normal D4Z4 length,
now described as FSHD2 [8]. A common, digenic mech-
anism has been proposed for FSHD 1 and 2, involving
abnormal epigenetic regulation of the D4Z4 macrosatellite
on 4qA in both forms of the disease. In FSHD 1 this is due
to a deletion in the heterochromatin (D4Z4) and in FSHD 2
is associated with loss-of-function mutations in SMCHD1 a
gene responsible for the maintenance of heterochromatin.
SMCHD1 mutations will result in hypomethylation of
D4Z4. If a permissive 4qA allele is present, both mecha-
nisms lead to an increased expression of the deleterious
retrogene DUX4 [4].
This increased understanding of the genetic mechanism
of FSHD has led to an increase in therapeutic strategies
with a number of pharmaceutical companies exploring
programmes for FSHD. However, there are many chal-
lenges in the development of therapies and moving them
from bench to bedside [9]. These include the recruitment of
sufficient numbers of well-characterised patients to ensure
meaningful and statistically significant results. Registries
provide a tool to help overcome this challenge by engaging
well-defined cohorts of patients interested in participating
in research [10]. Patient registries also have the potential to
collect data on disease burden and treatment interventions
with patient reported outcomes currently being used in
14 % of clinical trials [11]. The UK FSHD patient registry
(http://www.fshd-registry.org/uk), launched in May 2013,
provides an online portal in order to collect these
outcomes.
The registry is funded by Muscular Dystrophy UK
(MDUK) and was developed under the umbrella of the
global neuromuscular network TREAT-NMD (http://www.
treat-nmd.eu/) [12]. Here we describe the setup, progress
and utility of the registry together with the demographic
details of the patients registered in its first 2 years (May
2013–May 2015). We further discuss the accuracy and
completeness of the data.
Methods
Design and set up
Dataset
The UK FSHD registry collects all mandatory and highly
encouraged items outlined in this dataset for both patients
with FSHD1 and FSHD2 and is coordinated from the John
Walton Muscular Dystrophy Research Centre, Newcastle,
UK. The dataset comprises all the items identified at the
171st ENMC (European Neuromuscular Centre) workshop
on the care and management of FSHD [13]. This is a
minimal dataset designed to incorporate the features that
may define inclusion/exclusion criteria for clinical trials.
The mandatory items help to characterise the demograph-
ics, genetics, motor function and age of onset of the dis-
ease. The highly encouraged data includes additional
aspects that may help to better characterise the population
like eye and hearing involvement, respiratory status and
family history (Table 1). The registry goes beyond this
core dataset to collect additional information of interest,
identified by the UK researchers involved and the patient
community. After consultation with professional and
patient groups, outcomes relating to pain, quality of life
and scapular fixation were included. The outcomes used
include validated questionnaires; the McGill short form
pain questionnaire (MPQ) [14] and the Individualised
Neuromuscular Quality of Life Questionnaire (INQoL)
[15]. We also devised a universal pain assessment tool
(FSHD pain questionnaire, supplementary online material)
and a questionnaire about scapular fixation (supplementary
online material). These questionnaires have been devel-
oped specifically for the registry and require further
validation.
Governance and data access
The registry Steering Committee has 13 members includ-
ing clinical and genetic experts as well as representatives
from patient organisations and patients themselves (full
details in acknowledgments). The committee has input on
the strategic direction of the registry, acts as a data access
committee and ensures that the registry acts in the best
interests of patients. Terms of reference and standard
operating procedures have been developed for the com-
mittee (available in supplementary online material). The
registry is managed and maintained by a registry curator,
Libby Wood who has been responsible for the registries
development since 2012, with previous work in establish-
ing the steering committee being carried out by Karen
Rafferty from 2011.
The registry acts as a trusted intermediary between
researchers (academic or commercial) and patients them-
selves. A researcher may request aggregate de-identified
data through a proposal to the steering committee. The
committee do not provide ethical and scientific critique but
requires evidence these have been carried out by the
appropriate bodies if necessary. The committee evaluates if
providing the data will benefit the patients registered. A
vote takes place within 2 weeks, with data being provided
within 4 weeks of a positive outcome. The same evaluation
process is required before information is disseminated to
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help recruitment. Researchers do not receive direct access
to patients or to personal identifiable information. The
registry services are free of charge to academics and
charitable organisations but a fee structure is in place for
commercial requests (available in online supplementary
material).
Data collection
Potential participants hear about the registry through
patient support and advocacy groups (notably FSHD Sup-
port UK and Muscular Dystrophy UK), who provide
information at conferences, on websites and in newsletters.
In addition, clinicians received leaflets which are dis-
tributed at clinical appointments. Information about the
registry is also included on all diagnostic genetic reports
positive for FSHD issued by UK genetic laboratories. In all
cases the participants initiate registration themselves online
creating a personal account to start registration.
The UK FSHD Registry (http://www.fshd-registry.org/
uk) uses an advanced combined reporting system allowing
patient and clinician reported data to be united through a
single online portal. The information in the registry is
stored securely on a dedicated server at the Medical Centre
of Ludwig-Maximilians-Universita¨t in Munich with limited
access by named registry personnel only. The registry
software was developed by the operators to enable secure,
web-based collection of patient data. It is based on an
open-source stack including Java EE and the PostgreSQL
database server.
The registry is designed to allow the majority of the
information to be provided by the patients themselves, after
consenting online. Age appropriate information and con-
sent forms are available, enabling parents or guardians to
consent on behalf of those under 18 years old (available in
online supplementary material). The consent form allows
for future contact, for both communication and research, to
be made and for the additional data to be entered by a
nominated medical professional. Participants are able to
withdraw their consent at any time. All data remain the
property of the patient themselves and can be withdrawn at
any time.
The patient, as part of the registration process, will
nominate a neuromuscular specialist from a pre-defined list
who, using a separate online account, can confirm the
genetic details, add missing clinical information and check
for any inaccuracies in the patient data. Data from the
patient and clinician are combined in a single database. In
addition, genetic confirmation can be provided by the
diagnostic laboratories in the UK. Since 2015 Bristol
Genetics Laboratory (Bristol) is the only laboratory in the
UK providing the clinical diagnostic test for FSHD; how-
ever, historical genetic data can be provided by the
Northern Genetics service (Newcastle) and All Wales
Medical Genetic Service (Cardiff). The diagnosis for
FSHD2 has been available in Bristol since January 2014.
Participants are encouraged to update details annually
allowing for the collection of longitudinal data. Where
access to the internet is not available an alternative paper
version of the registry questionnaire and consent proce-
dures are provided.
Ethics approval
The registry has received full ethical (Newcastle and North
Tyneside 113/NE/0048, February 2013), management
(Newcastle upon Tyne Hospitals Trust R&D 6573,
February 2013) and data protection (Caldicott February
2013) approvals for conducting these activities in the UK.
Data analysis
For purposes of analysis of the current data we have con-
sidered FSHD1 when the genetic report states that the
patient has a contraction of the D4Z4 macrosatellite on
chromosome 4qA of less than 38 kb, and FSHD2 if the
Table 1 Items defined in the internationally agreed core dataset for FSHD registries (full questionnaire in online supplementary material) [16]
Mandatory items Highly encouraged items
Personal data (name, date of birth, address, phone, email)
Genetic test result (FSHD1, FSHD2)
Clinical data (facial weakness, shoulder weakness, foot weakness, hip girdle weakness)
Onset of muscle weakness
Best current motor function (ambulatory, non-ambulatory)
Wheelchair use
Ventilation (non-invasive, invasive)
Age of onset for selected FSHD symptoms
Retinal vascular disease attributable to FSHD
Hearing loss
Scapular fixation (one shoulder, both shoulders)
Pregnancy (females only)
Family history
Ethnic origin
Other registry involvement
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genetic result confirms a SMCHD1 mutation with a per-
missive 4qA allele or hypomethylation. When this data was
not available we used the patient self-reported diagnosis of
FSHD1 or FSHD2. All statistics discussed here are
descriptive and presented as percentages of the whole
cohort (n = 518), FSHD1 cohort (n = 475) or FSHD 2
cohort (n = 9) unless otherwise stated. All means are
presented ± the standard deviation.
Results
Progress of data collection and other initiatives
The registry was launched at a patient information day in
the UK, and presented to around 90 delegates. Two months
after the launch 225 people had registered. Over the first
2 years (25 months) period an average of 21 people have
registered per month. Thirty-four doctors have agreed to
take part in the registry and provide genetic data. Two
hundred and twenty-six patients have selected a clinician to
provide additional details. Of the 518 people registered,
260 have logged into update their data, 121 have not log-
ged in after an annual reminder and 137 have not yet been
registered for 12 months (Online Supplementary Material
Fig. 1: Rate of patient enrolment; May 2013 to May 2015.)
The additional outcomes (pain, scapular fixation and
quality of life) have been completed by the majority of
people. Of the 518 people registered in total 425 (82 %)
provided answers to InQoL, 479 (92 %) answered the
McGill pain questionnaire and 468 (90 %) answered the
FSHD specific pain questionnaire. Within the core ques-
tionnaire 46 people report having had scapular fixation, of
which 40 have completed the additional questionnaire.
In its first 2 years, the registry has helped recruitment
into an international natural history study for infantile onset
FSHD ‘‘A multicentre collaborative study on the clinical
features, expression profiling, and quality of life of infan-
tile onset facioscapulohumeral muscular dystrophy.’’
(ClinicalTrials.gov Identifier; NCT01437345). Interroga-
tion of the registry database identified 33 patients meeting
some or all of the inclusion criteria. All patients were
contacted and five were included in the study. This made
up 42 % of the total participant requirement for the UK
study site (John Walton Muscular Dystrophy Research
Centre); the remaining participants were identified from the
local clinic population.
Demographics
Between May 2013 and May 2015 a total of 518 patients
registered with the UK FSHD Patient Registry, an average
of 21 patients per month from all across the UK (Fig. 1).
Most patients live in the south of England with the major
clustering around London. Other clusters surround the
areas of Liverpool/Manchester, Newcastle and Edinburgh.
These clusters represent most probably a higher population
density and the existence of centres with neuromuscular
specialists. Of these 475 reported being affected by FSHD
1 (91.7 %), 9 reported FSHD2 (1.7 %) and 34 (6.6 %)
reported that they had a yet to be confirmed diagnosis.
Excluding the patients with unconfirmed diagnosis,
98.14 % of patients were reported as FSHD1 and 1.9 % as
FSHD2. Those with an unknown diagnosis have been
excluded from further analysis. All data mentioned has
been reported by patient themselves with the exception of
genetic confirmation which has been provided by the
treating neuromuscular specialist or central diagnostic lab.
The self-reported diagnosis was checked against the
result of the genetic testing when available. FSHD1 is
genetically confirmed in 307 cases, 286 of which had
identified as having FSHD1, three misreported having
FSHD2, and 18 reported an unknown diagnosis or left this
question blank. We have a genetically confirmed diagnosis
for two FSHD2 patients, matching the self-report in both
cases.
The mean age of all patients included in the registry is
47.82 ± 16.08; (range 6–83) years. There are 243
Fig. 1 Distribution of patients across the UK, each pin represents an
individual registered
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(50.20 %) males and 241 (49.79 %) females registered
with a slight non-significant predominance of females in
the younger age groups (0–19). Considering only the 475
FSHD1 patients, there is also an even distribution across
genders (239 Males, 236 Females) and the current age
ranges from 4 to 83 years old (mean 47.7 ± 16.13),
60.21 % (286) of patients are between the ages of 40 and
70 years old (Fig. 2). The age range of the nine FSHD2
patients is from 19 to 67 with a mean of 50 (±13.85) years,
with an even distribution between genders (5 males; 4
females). Detailed family history is not collected; however,
the majority of patients are aware of at least one additional
family member being affected (father 79, mother 131,
sibling 145, and other family member 157) (Table in online
supplementary material).
The ethnic origin of all FSHD patients is predominantly
Caucasian, in FSHD1 this makes up to 89.9 % (427) of
those registered, [Asian 20 (4.2 %), black African 1
(0.2 %), mixed 4 (0.84 %), declined 13 (2.7 %), other 10
(2.1 %)] and in FSHD2 8 of the 9 (88.9 %) patients
reported Caucasian ethnicity with the remaining patients of
unknown ethnic origin. Comparison with the ethnic dis-
tribution in the 2011 Census the different ethnic groups are
evenly distributed apart from the black African group that
are at a lower percentage than the general population,
although applying a two-sample test of proportions the
difference is non-significant (Table 2).
Clinical data
Fourteen records were excluded from this analysis, 12
FSHD1 and two FSHD2, these records have been excluded
due to incomplete patient reported data. Excluded records
had one or more of the following data items missing; to
current motor function, hearing loss, wheelchair use, facial
weakness, foot drop, hip girdle weakness and periscapular
weakness. The analysis of the results showed that of the
FSHD1 patients 82.5 % (n = 382) are ambulant although
45.1 % (n = 171) of these report that they require some
assistance (e.g., using a cane or wheelchair part time). All
of the FSHD2 patients remain ambulant with three
requiring assistance. Muscle weakness is often reported to
begin in multiple areas most commonly including facial
muscles (59.18 %), with shoulder girdle weakness reported
first in 53.33 % of cases, foot dorsiflexion weakness in
22.45 % and hip-girdle in 14.79 % (Table 3).
Additional symptomatic information is available for 463
FSHD1 patients registered, 17.28 % (n = 80) reported
hearing loss, evenly split across genders (46.25 % female;
53.75 % male) with 38.57 % (n = 27/70) reporting hear-
ing loss before the age of 40 years. Retinal vascular disease
is reported in just 10 patients 6 males and 4 females, with a
mean age of 45.6 years (range 25–69).
A total of 9.85 % (n = 46) patients report having
undergone scapular fixation surgery, 27 (58.69 %) of them
had the procedure on both shoulders. The first operation
has been performed at a mean age of 28.82, with 56 %
having the surgery before age 30 years.
Thirty-seven (7.9 %) patients 22 males and 15 females,
with a mean age of 50.96 years (range 20–76) reported the
use of ventilation, with five (13.5 %) describing this as full
time ventilation. Thirty-three of these (89.2 %) describe
their current best motor function as requiring at least some
assistance when walking.
A more in depth analysis of the clinical data will be
discussed in a subsequent study.
Discussion
Successes and limitations
The UK FSHD patient registry contains information on
over 518 FSHD patients, 475 of whom are confirmed to
have FSHD1. Given the published FSHD1 prevalence of
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Fig. 2 Distribution of age and gender within the UK FSHD patient
registry
Table 2 Comparison between different ethnic groups
Ethnic group Census 2011 (%) Registry (%)
Caucasian 87.10 89.90
Asian 6.90 4.20
Black 3.00 0.20
Mixed 2.00 0.84
Other 1 2.10
Declined 2.70
UK general population vs patients in the registry
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3.95 FSHD1 patients per 100,000 in North East England
[1] and based on a population of 64.1 million in UK in
2014, this would equal 31 % of population coverage. The
primary goal of the registry is not to capture all patients
within the UK but rather to identify patients who are
interested in participating in research. This should be
considered when drawing clinical conclusions as the reg-
istry is likely to represent a biased sample of the more able
and willing patients or arguably could also represent the
more severely affected that are more engaged to enrol.
FSHD1 is the most common form of the disease with
approximately 95 % of patients falling into this category,
and this is similar in the UK registry population (91.7 %).
The remaining 5 % are considered as FSHD2 patients [16]
similar to the 8.3 % of the UK registry population. It will
be interesting to assess whether there will be an increase of
FSHD2 diagnosis and registration following the relatively
recent development of confirmatory genetic testing for
FSHD2.
Most of the patients registered are ambulant and
although this could be due to a recruitment bias, when we
compare our data with population based collected data the
percentage of ambulant patients is similar, we therefore
believe this self-reported data transmits and accurate
snapshot of the general FSHD population [17–19]. The
same is true when we look at the first location of muscle
weakness, with facial and shoulder girdle being the most
common locations. As already reported in the literature,
distal or proximal lower limb involvement as the first
manifestation is not unusual. In a previous report the
frequency was 13 % for foot drop and 7 % for proximal
lower limbs [20], the percentage is lower than in our
population as they were considered as isolated manifesta-
tions and while in our cases the patients reported simulta-
neous locations for the beginning of the symptoms. An
interesting aspect is the high incidence of hearing loss
either under or above the age of 40. Further study is needed
to determine whether this self-reported problem is in fact
associated with any greater degree of hearing loss within
the general population. From the recently published evi-
dence-based guidelines from the American Academy of
Neurology (AAN) [21] the recommendation regarding
hearing loss is to screen patients with childhood onset as
the prevalence of clinically relevant hearing loss is not
clear in the general population. Respiratory involvement in
FSHD is considered rare. From the literature and according
to the guidelines of the AAN evidence from 2 studies
suggests that respiratory involvement with an estimated
frequency from 1.25 to 13 % and once more the self-re-
ported respiratory status in our population is in accordance
with this.
In asking the patients to provide the majority of the data
through electronic communication, it has been possible to
identify a large number of patients with FSHD in the UK in
a short time frame and limited resources. A large amount of
accurate and complete data now exists within the registry
and is available to support the research community. In
addition, there is a cohort of patients interested and able to
participate in future clinical research. However, it should
be noted the data provided are subjective and are not a
Table 3 Clinical summary of
participants reporting a
diagnosis of FSHD1 in the UK
FSHD patient registry
FSHD 1
(n = 463a)
Genetically confirmed
(n = 298)
% of genetically confirmed
reporting symptom (%)
Hearing loss
Yes/no (unknown) 80/345 (38) 54/222 (22) 18.12
Retinal vascular diseaseb
Yes/no (unknown) 10/371 (65) 9/230 (59) 3.02
Current motor function
Ambulant 211 143 47.99
Ambulant with assistance 171 112 37.58
Non-ambulant 81 43 14.43
Wheelchair use
Full-time 82 45 15.10
Part-time 103 65 21.82
None 278 188 63.09
Facial weakness 347 214 71.81
Scapular weakness 428 270 90.60
Hip girdle weakness 346 214 71.81
Foot drop 341 215 72.15
a 12 records excluded for missing or incomplete patient reported data
b An additional 17 participants did not respond to the question about retinal vascular disease n = 446
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substitute for data collected in a natural history study or
clinical trial collected under GCP guidelines.
The input of detailed genetic data was delayed by the
limited time and resources available to consultants within
the NHS. This has been greatly increased through collab-
oration with diagnostic laboratories in the UK (Northern
Genetics Service and Bristol Genetics Laboratory) that are
able to provide details directly to the registry, as covered
by the informed consent. In order to increase the coverage
of genetic diagnosis further we will explore ways to receive
this data directly from patients.
The registry has achieved its primary aim of helping to
facilitate and accelerate recruitment into trials, evidenced
by the infantile onset study mentioned above. The use of
the registry led to the UK site (John Walton Muscular
Dystrophy Research Centre) recruiting 70 % more patients
than would have been available through local contacts
alone. This significant increase is particularly important in
rare diseases. Furthermore the response rates ([80 %) to
the additional research questionnaires show that the utility
of the registry goes above and beyond its primary purpose.
The registry continues to consult with researchers in the
UK and globally to ensure its use in clinical research,
furthermore it could be utilised to develop and disseminate
standards of care.
For the last few years, the European Union policy on
Rare Diseases has stressed the need for an active collabo-
ration in and between Member States as a way to promote
equal access to care and to make the maximum use of the
resources available for rare disease patients. The tools
developed for this were at the level of the Member States
the creation of National Plans for Rare Diseases and the
nomination of Centres of Reference/Expertise; at a Euro-
pean level the future constitution of European Reference
Networks are meant to help to fulfil that aim. For these
instruments to be of use; data sharing and accurate, well
established registries like the present one are an upmost
requirement.
The registry has a mean recruitment rate of 21 regis-
trations per month. A number of other registries utilise the
same dual reporting system and have achieved similar
rates, when taking into account different disease prevalence
rates. The UK myotonic dystrophy registry (http://www.
dm-registry.org/uk) has a mean rate of 16 per month while
the incidence of myotonic dystrophy in the UK is thought
to be higher than that of FSHD [1]. The Global FKRP
registry (http://www.fkrp-registry.org/uk) collecting infor-
mation about people with mutations in the FKRP gene has
a lower rate of recruitment at an average of seven people
joining per month, this is a much rarer condition (about 1 in
100,000 [1, 22]) however has global coverage. The per-
sistent rate of inclusion seen in the UK FSHD registry
suggests that there is an engaged and motivated FSHD
population in the UK interested in participating and being
informed about research.
Future considerations
The registry now contains a wealth of data on a subset of
the UK FSHD population; the next steps are to carry out an
in depth analysis on this data, in particular looking at the
progression of the condition. The registry allows for the
collection and analysis of longitudinal data, and that
analysis, particularly in relation to pain and quality of life
may provide an interesting resource to improve care of
FSHD patients in the UK. The registry will also be able to
inform on genotype phenotype correlation for FSHD1 and
FSHD2.
A sub study is planned using the information collected
on scapular fixation, contacting the surgeons who per-
formed the procedure to create a more in depth picture of
how this operation is carried out in the UK. We hope this
coupled with the detailed patient experience could help
clinicians better inform patients considering this procedure
in the future. Further analysis will also be carried out on the
remaining clinical data to generate hypothesis for future
research which may improve standards of care.
The UK FSHD patient registry contains all of the
mandatory and highly encouraged items outlined in an
internationally agreed dataset [13]. This data set is known
to be collected by 15 registries either established or in the
setup stage (Italy, Croatia, Netherlands, Ukraine, Spain,
Argentina, Chine, Czech Republic, Georgia, UK, USA,
Canada, Australia, Egypt and New Zealand) under the
TREAT-NMD umbrella. This comparability could allow
the creation of a Global FSHD registry, something
TREAT-NMD has achieved successfully for paediatric
neuromuscular diseases Duchenne muscular dystrophy and
spinal muscular atrophy [23, 24]. The UK FSHD Registry
would welcome any efforts of this kind from TREAT-
NMD and would hope to be at the forefront of such
developments. Furthermore there is an increased move-
ment towards harmonisation of data among the wider rare
disease community, not only with registries but also con-
sidering biobank, omics and imaging information. The UK
FSHD registry has been working with RD-Connect as it
pilots a number of initiatives working towards this goal
[17–20].
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